GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2007

Oncolys and Tacere Forge Alliance to Develop RNAi HCV Drug

  • Oncolys BioPharma signed an agreement to develop Tacere Therapeutics’ drug candidate for the treatment of HCV. TT-033 is an RNAi-based product.

    Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033. “HCV continues to be a significant public health crisis in Japan, China, and Korea, and we look forward to Oncolys' expert guidance along the regulatory and marketing path in Asia," remarks Sara M. Hall, Tacere’s president and CEO.

    Tacere reports that it will begin IND-enabling studies on TT-033 shortly and plans to enter Phase I trials in late 2008.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?